SecurityCBS.A / CBS Corp. (124857103)
Chairman, President & CEOMOONVES LESLIE
IndustryTelevision Broadcasting Stations
Institutional Owners56
Institutional Shares36,479,562 - 10.68%
Common Shares Outstanding2341,480,807 shares (as of 2018-03-31)
Institutional Value$ 339,527,000 USD
Related CBS / CBS Corp.
124857AH6 / Cbs Corp 1.95% 07/01/17
124857AG8 / Cbs Corp 3.375% 03/01/22
124857AE3 / Cbs Corp 4.3% 02/15/21
124857AJ2 / Cbs Corp 4.85% 07/01/42
124857AF0 / Cbs Corp 5.9% 10/15/40
CPV / CBS Corp. 6.75% Senior Bond Due 3/27/2056
124857AA1 / Cbs Corp. 7.625% Sr. Debentures 1/15/16
124857AC7 / Cbs Corp 8.875% 05/15/19
CBS.WD / CBS Corporation
925524AU4 / Viacom Corp 4.625% Senior Notes 05/15/18
925524AV2 / Viacom Corp 5.500% Senior Debentures 05/15/33
925524AH3 / Viacom Corp 7.875% Senior Debentures 07/30/30
960394AP9 / Westinghouse Cr Corp Notes 8.875% 06/14/14

Institutional Stock Ownership and Shareholders()

CBS.A / CBS Corp. Institutional Ownership

CBS Corp. (NYSE:CBS.A) has 56 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 36,479,562 shares. Largest shareholders include National Amusements Inc /md/, Gruss Capital Management LP, Gamco Investors, Inc. Et Al, Gabelli Funds Llc, Renaissance Technologies LLC, Meag Munich Ergo Kapitalanlagegesellschaft Mbh, Millennium Management Llc, Pacific Heights Asset Management Llc, Dimensional Fund Advisors Lp, and Vanguard Group Inc.
CBS Corp. (NYSE:CBS.A) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/cbs.a"><img src="https://images.fintel.io/us-cbs.a-so.png" alt="CBS.A / CBS Corp. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-14 13F-HR Gruss Capital Management LP 2,480,000 2,479,900 -0.00 148,254 127,566 -13.95
2018-04-20 13F-HR Seacrest Wealth Management, Llc 306 306 0.00 18 16 -11.11
2018-05-03 13F-HR Jacobi Capital Management LLC 1,050 1,050 0.00 60 53 -11.67
2018-04-20 13F-HR FIRST MANHATTAN CO 20,000 20,000 0.00 1,195 1,028 -13.97
2018-04-23 13F-HR Advisory Services Network, LLC 8 0
2018-05-11 13F-HR CITIGROUP INC 305 5 -98.36 18 0 -100.00
2018-04-13 13F-HR North Star Investment Management Corp. 270 270 0.00 16 14 -12.50
2018-04-16 13F-HR NWAM LLC 4,039 4,840 19.83 238 249 4.62
2018-04-24 13F-HR Baystate Wealth Management LLC 20 1
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 10,700 0 -100.00 635 0 -100.00
2018-05-10 13F-HR GREAT WEST LIFE ASSURANCE CO /CAN/ 29 1
2018-05-15 13F-HR DEUTSCHE BANK AG\ 8,824 11,534 30.71 527 593 12.52
2018-05-18 13F-HR LEVIN CAPITAL STRATEGIES, L.P. 4,603 0 -100.00 275 0 -100.00
2018-05-14 13F-HR BROWN ADVISORY INC 11,549 12,249 6.06 690 630 -8.70
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 60,751 101,510 67.09 3,605 5,246 45.52
2017-01-13 13F-HR MetLife Securities, Inc 745 730 -2.01 41 47 14.63
2018-05-09 13F-HR NORTHERN TRUST CORP 6,597 4,638 -29.70 395 238 -39.75
2018-04-16 13F-HR WESPAC Advisors SoCal, LLC 122 122 0.00 7 6 -14.29
2018-05-14 13F-HR Resources Investment Advisors, Inc. 700 500 -28.57 42 26 -38.10
2018-04-18 13F-HR REGIONS FINANCIAL CORP 157 157 0.00 9 8 -11.11
2018-05-15 13F-HR VANGUARD GROUP INC 12,995 37,417 187.93 771 1,934 150.84
2018-04-25 13F-HR BECK MACK & OLIVER LLC 4,200 4,200 0.00 251 216 -13.94
2018-05-15 13F-HR Walleye Trading LLC 12,145 5,982 -50.75 726 308 -57.58
2017-02-10 13F-HR BlackRock Fund Advisors 4,548 4,955 8.95 252 321 27.38
2018-05-09 13F-HR BlackRock Inc. 20,521 6,652 -67.58 1,227 342 -72.13
2018-04-18 13F-HR/A FNY Partners Fund LP 54 254 370.37 3 13 333.33
2018-05-11 13F-HR Harbor Advisors LLC 5,000 5,000 0.00 299 257 -14.05
2018-05-15 13F-HR CAPTRUST FINANCIAL ADVISORS 34 34 0.00 2 2 0.00
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 9,916 10,293 3.80 592 530 -10.47
2018-05-11 13F-HR First Allied Advisory Services, Inc. 353 0 -100.00 21 0 -100.00
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 155 153 -1.29 9 8 -11.11
2018-05-09 13F-HR GAMCO INVESTORS, INC. ET AL 1,854,038 1,702,797 -8.16 110,834 87,592 -20.97
2017-02-13 SC 13G/A NATIONAL AMUSEMENTS INC /MD/ 29,882,639
2018-05-07 13F-HR GREAT LAKES ADVISORS, LLC 14,650 0 -100.00 876 0 -100.00
2018-05-02 13F-HR MEAG MUNICH ERGO KAPITALANLAGEGESELLSCHAFT MBH 17,435 108,932 524.79 1,039 5,627 441.58
2018-05-15 13F-HR Pacific Global Investment Management CO 5,325 5,328 0.06 316 274 -13.29
2018-05-09 13F-HR PARK CIRCLE Co 500 500 0.00 30 26 -13.33
2018-05-14 13F-HR MORGAN STANLEY 3,381 4,721 39.63 202 243 20.30
2018-05-15 13F-HR Nokota Management, LP 436,973 0 -100.00 25,781 0 -100.00
2018-04-23 13F-HR Sterling Investment Advisors, Ltd. 80 80 0.00 5 4 -20.00
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 4 0 -100.00 0 0
2018-05-15 13F-HR BARCLAYS PLC 0 8 0 0
2018-04-30 13F-HR Glassman Wealth Services 254 255 0.39 15 13 -13.33
2018-05-14 13F-HR MONETA GROUP INVESTMENT ADVISORS LLC 200 200 0.00 12 10 -16.67
2018-05-11 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 1,251 1,251 0.00 75 65 -13.33
2018-05-04 13F-HR Sandy Spring Bank 160 160 0.00 10 8 -20.00
2018-04-23 13F-HR Pineno Levin & Ford Asset Management, Inc. 7,190 7,140 -0.70 424 367 -13.44
2018-05-09 13F-HR GABELLI FUNDS LLC 1,522,300 1,507,300 -0.99 91,003 77,536 -14.80
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 6,674 30,811 361.66 396 1,592 302.02
2018-05-10 13F-HR Stratos Wealth Partners, LTD. 40 40 0.00 2 2 0.00
2018-05-08 13F-HR PACIFIC HEIGHTS ASSET MANAGEMENT LLC 100,000 100,000 0.00 5,934 5,168 -12.91
2018-05-15 13F-HR HighTower Advisors, LLC 3,517 0 -100.00 211 0 -100.00
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 84 94 11.90 5 6 20.00
2018-05-15 13F-HR UBS Group AG 1,775 2,313 30.31 106 119 12.26
2017-02-10 13F-HR BlackRock Advisors LLC 350 350 0.00 19 23 21.05
2018-05-09 13F-HR GABELLI SECURITIES, INC. 9,242 9,242 0.00 552 475 -13.95
2018-05-14 13F-HR Renaissance Technologies LLC 315,100 315,600 0.16 18,837 16,234 -13.82
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 68,177 63,930 -6.23 4,046 3,304 -18.34
2018-05-15 13F-HR CSS LLC/IL 296 15
2018-04-16 13F-HR BALDWIN BROTHERS INC/MA 3 3 0.00 0 0
2018-05-15 13F-HR TANAKA CAPITAL MANAGEMENT INC 50,246 20,968 -58.27 2,965 1,078 -63.64
2017-10-26 13F-HR Acrospire Investment Management LLC 29 0 -100.00 2 0 -100.00
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 862 0 -100.00 52 0 -100.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 1,766 1,766 0.00 106 91 -14.15
2018-05-08 13F-HR US BANCORP \DE\ 30 30 0.00 2 2 0.00

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Regulators Will Review Requirements for Children's Programming After Plea by Broadcasters - Bloomberg

2018-06-20 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (71-0)

CBS to expand 'Star Trek' with five-year deal for new TV shows

2018-06-19 reuters
LOS ANGELES, June 19 (Reuters) - U.S. broadcast network CBS will expand the popular “Star Trek” science-fiction franchise with new series, mini-series and animation under a production deal announced on Tuesday. (55-0)

Walt Disney Co Stock Is Finally Set to Move, But in Which Direction?

2018-06-15 investorplace
Walt Disney Co (NYSE:DIS) stock hasn’t moved in over three years now. Since the beginning of 2015, Disney stock has traded almost without exception between $90 and $120 per share. And at the moment, it sits just south of the midpoint of that range. (187-0)

Disney-Fox? Apple-CBS? Facebook-Bravo? - Bloomberg

2018-06-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (282-1)

Apple and Amazon Don’t Need to Buy Hollywood - Bloomberg

2018-06-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (328-0)

CUSIP: 124857103